Join us at our Prostate Cancer Symposium which will delve deeper into advancements in surgical techniques and therapies that are transforming the landscape of prostate cancer management. Hear from our panel of specialists who will present innovative approaches to treatment modalities available for patients, the role of surgical options on locally-advanced cases, and the integration of targeted therapies with treatments for metastases.
Our panel discussions will offer practical insights into treatment plans, side effect management, and improving patient outcomes. A special focus will be given to the multidisciplinary approaches required to address the complexities of late-stage prostate cancer, highlighting the important collaboration between surgeons, oncologists, and healthcare providers.
Our Speakers
Dr. Andrew Tan
Nuclear Medicine Specialist
Dr. Andrew Tan Eik Hock received his MBBS from the National University of Singapore School of Medicine in 2001. He was admitted as a Fellow of the Royal College of Radiologists in the United Kingdom in 2008 and the Academy of Medicine of Singapore in 2009, and was awarded a Diplomate in Nuclear Cardiology from the Certification Council in Nuclear Cardiology in the United States in 2011. Dr. Tan is currently a Nuclear Medicine consultant at Farrer Park Hospital.
His main clinical interests are in theranostics and neurodegenerative disorders, and he has been on training attachments to Zentralklinic Bad Berka in Germany, European Institute of Oncololgy in Italy and Austin Health in Melbourne Australia. He currently serves at the president of the Singapore Radiological Society, and is a member of the World Association of Radiopharmaceutical and Molecular Therapy.
Dr. Tan's specialty interests are neurogenerative diseases and theranostics.
Dr. Png Keng Siang
Urologist
Dr. Png Keng Siang is a Senior Consultant Urologist who has performed more than 800 robotic and laparoscopic procedures over the span of his career. His area of expertise includes robotic and other minimally invasive surgical procedures. He specializes in prostate and kidney cancer as well as other conditions such as benign prostate enlargement and kidney stones.
Prior to private practice, Dr. Png was Director of the Robotic Urological Surgery Fellowship Program at Tan Tock Seng Hospital, Director of the National Healthcare Group’s Urology Residency Program and Adjunct Assistant Professor at the NUS Yong Loo Lin School of Medicine. Currently, he serves as the JCST Site Accreditor for the Urology Residency Program.
Dr. Png completed his urology specialist training in Singapore followed by a clinical fellowship in robotic and laparoscopic surgery at the Indiana University School of Medicine in the U.S. He is the first Singapore urologist to be conferred the Fellow, American College of Surgeons (FACS).
Dr. Png has trained numerous urologists both locally and abroad in minimally invasive surgery. He performed live surgery demonstrations in Myanmar and Vietnam, pioneering the robotic surgery program in Ho Chi Minh City by performing the first three robotic urological operations in the history of Vietnam.
Apart from clinical work, Dr. Png is also actively involved in several academic organizations. He is the founding member and Vice President of the Robotic Surgery Society of Singapore. Dr. Png was the Honorary Secretary of the Singapore Urological Association, where he also served for eight years on its Executive Committee. He is an international member of the American Urological Association and Endourological Society and has served in the Education Committee of the Society of Urologic Robotic Surgeons.
Dr. Png's specialty interests are benign prostate hyperplasia, bladder cancer, erectile dysfunction and men's health.
Dr. Toh Chee Keong
Medical Oncologist
Dr. Toh Chee Keong is a medical oncologist who sub-specializes in thoracic oncology (lung cancer, thymic cancer), genitourinary oncology (prostate, kidney, bladder and testicular cancers) as well as head and neck cancers.
He worked at the National Cancer Centre Singapore for most of his career, with a 3-year stint intercalated at Raffles Cancer Centre where he was director of clinical research before joining Curie Oncology. He was the lead of the Lung Cancer Consortium project at National Cancer Centre who coordinated lung cancer research in Singapore, paving the way for many publications and discoveries. He was also part of the team who won the Large Collaborative Grant for their research on ‘Next-Generation Clinical Trials and Integrative Research for Fighting Lung Cancer’ awarded by National Medical Research Council.
He graduated from National University of Singapore with the Gibbs Gold Medal in 1995, followed by MRCP (UK) in 2000 and specialist accreditation in Medical Oncology in 2004. Under the Health Manpower Development Programme, he was in the United States at Burnham Institute in La Jolla and Moores Cancer Centre in San Diego.
Throughout the years, Dr. Toh was involved in clinical work, clinical trials and teaching. Among his many achievements is his published work on the clinical characteristics of lung cancer among never-smokers, one of the earliest publications in the world during a time when the molecular characteristic of this group of patients was not known yet. It was later discovered that lung cancer in never-smokers formed a big group in the Asian population.
Dr. Toh was one of the first oncologists in Singapore to administer high dose interleukin-2 as a form of immunotherapy treatment for kidney cancer and melanoma. Immunotherapy then transitioned to checkpoint inhibitors over the years and became a cornerstone in the treatment of many cancers today. He has led and was a co-investigator in many clinical trials. He was also a member in the workgroup for the Singapore Cancer Network (SCAN) guidelines for lung cancer, kidney cancer, prostate cancer and bladder cancer. In the area of teaching, he was Assistant Professor at the National University of Singapore's Yong Loo Lin School of Medicine and the Duke-NUS Medical School.
Dr. Toh hopes to bring with him the extensive clinical experience to Curie Oncology to provide good experiential care to the patients, encourage them and let them know that someday, spring will come.
Dr. Toh's specialty interests are genitourinary oncology (prostate, kidney, bladder and testicular cancers), and thoracic oncology (lung cancer, thymic cancer).
